Biodesix (NASDAQ:BDSX – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.07, Fidelity Earnings reports. During the same quarter in the previous year, the business earned ($0.41) EPS. Biodesix updated its FY 2022 guidance to EPS.
Biodesix Stock Down 4.3 %
BDSX traded down $0.12 on Friday, reaching $2.77. The company’s stock had a trading volume of 107,957 shares, compared to its average volume of 117,100. The stock has a 50 day moving average of $1.76 and a two-hundred day moving average of $2.15. The company has a market capitalization of $110.02 million, a price-to-earnings ratio of -1.54 and a beta of 1.20. Biodesix has a fifty-two week low of $1.25 and a fifty-two week high of $10.22.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on BDSX shares. BTIG Research reiterated a “buy” rating and set a $10.00 price target (down from $17.00) on shares of Biodesix in a research note on Thursday, April 14th. Cowen started coverage on shares of Biodesix in a research note on Wednesday, April 20th. They set an “outperform” rating on the stock. Cowen started coverage on shares of Biodesix in a research note on Wednesday, April 20th. They set an “outperform” rating on the stock. Finally, Canaccord Genuity Group cut their target price on shares of Biodesix from $10.00 to $7.00 in a research note on Thursday, May 12th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Biodesix has an average rating of “Moderate Buy” and a consensus price target of $12.50.
Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
- Get a free copy of the StockNews.com research report on Biodesix (BDSX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.